Tag: orphan drugs

Orphan Drugs—Exploring the Challenges of Pricing, Reimbursement, and Funding

Glasgow, Scotland, UK—6 November 2017—ISPOR, the professional society for health economics and outcomes research (HEOR), held several sessions on the topic of orphan drugs at its 20th Annual European Congress, currently being held 4-8 November 2017 in Glasgow, Scotland, UK.

Posted in Announcements, ISPOR News & Press Tagged with: , , ,

ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXPLORES HOW HTA BODIES CAN CONSIDER THE VOICE OF PATIENTS WITH RARE DISEASES

Vienna, Austria—31 October 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR)  led an interesting discussion session this afternoon entitled, From Testimonials to Qualitative Research Embedded in Clinical Trials: How Do Health Technology Assessment Bodies Consider the Voice of Rare

Posted in Announcements, ISPOR News & Press Tagged with: , , , , ,

STUDY REVEALS SIGNIFICANT GLOBAL VARIATION IN THE DEFINITION OF THE TERM “RARE DISEASE”

First International Study of Its Kind Published in ISPOR’s Value in Health  Princeton, NJ—October 26, 2015—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) published results of an expansive global review answering a basic scientific question, “How do you describe

Posted in Announcements, ISPOR Journals, ISPOR News & Press, Value in Health Tagged with: , , , ,

WHAT`S GOING ON WITH THE TURKISH ORPHAN DRUGS MARKET?

Ankara, Turkey – Many countries and regions have already defined health policies on orphan drugs for rare diseases. Although there is no official definition in Turkey, all orphan drugs are covered by reimbursement, regardless of their market authorization status.

Posted in Announcements, Health Policy Analyses, Value in Health Regional Issues Tagged with: , , , , , , , ,

Improving Clinical Trial Participation Through Patient-Centered Trial Design

Baltimore, MD, USA – Many people are reluctant to participate in clinical trials.  This reluctance stems from the perception of risk while not seeing any clear benefit to participation.  The exception is when an individual has a condition for which there

Posted in Policy Perspectives, Value in Health Tagged with: , , , , ,

Valuing Rare Disease Medicines – We Can Do Better

London, United Kingdom – Many rare diseases, often severe and life-threatening, cannot be treated. The small numbers of patients affected make it time-consuming and costly to compile evidence about treatments. Organisations that pay for health care recognise that a special approach

Posted in Brief Report, Value in Health Tagged with: , , , ,